Progress towards ELF Since 2004 in India

Progress towards ELF Since 2004 in India

• 2004: National campaign of Mass Drug Administration (MDA) with DEC - launched in 202 districts.
  
  
• 2006: NTF recommended DEC+Albendazole in country.
  
  
• 2007: MDA programme was further scaled up to cover all 256 districts
  • WHO increased donation of Albendazole
  • Medical colleges and ICMR/NCDC involved to assess
  • Financial allocation increased to Rs. 50-60 cr per annum
  • IEC/BCC intensified under overall NHM

• 2013: Validation started through Transmission Assessment Survey (TAS)
  
  
• 2016: Integration with NDD campaign (Feb & Aug)
  
  
• 2018: 10^th GALEF meeting held & launched Accelerated Plan of Elimination of Lymphatic Filariasis (APELF)
  
  
• 2018: Triple Drug Therapy (IDA) i.e. DEC + Albendazole + Ivermectin in scheduled districts in phase wise manner.
  
  
• 2019: Revision of financial norms for morbidity management of Lymphoedema Patient from Rs. 150 to Rs. 500
  

• 2020 - Expansion of IDA (Domestic procurement of Ivermectin)

• 2021 – Introduction of Block Level Strategy

• 2022 - Approval and securing funds for implementation of block level strategy and first Independent Joint Monitoring mission on LF in November 2022.

• 2023 - LF Symposium held on 13th January 2023 with launch of enhanced 5-pronged strategy with bi-annual MDA.

• 2024 - Launch of Revised ELF guidelines by Shri Prataprao Jadhav, Hon’ble Minister of State (Independent Charge) of Ministry of AYUSH and Ministry of Health & Family Welfare, Government of India along                  with the launch of August 2024 MDA campaign.

• 2025 - National Lymphatic Filariasis Training of Trainer on Revised ELF Guidelines along with effectiveness of LF IEC workshop.